Vitória Capelli de Melo

Mrs. Vitória Capelli de Melo

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2024 in Purinergic Signalling
Verified
Journal Article
Closed access
PDF file
GBGeórgia de Carvalho Braga
Geórgia de Carvalho Braga
JCJoão Victor Coiado
João Victor Coiado
VMVitória Capelli de Melo
Vitória Capelli de Melo
BLBrenno Bianchoni Loureiro
Brenno Bianchoni Loureiro
MBMARGARETE DULCE BAGATINI
MARGARETE DULCE BAGATINI

Verified
Journal Article
Open access
PDF file
GFGeile Fistarol
Geile Fistarol
LOLuiz A. de Oliveira
Luiz A. de Oliveira
GSGilnei Bruno da Silva
Gilnei Bruno da Silva
DMDaiane Manica
Daiane Manica
MHMarceli Cleunice Hanauer
Marceli Cleunice Hanauer
MBMARGARETE DULCE BAGATINI
MARGARETE DULCE BAGATINI
Pituitary neuroendocrine tumors (PitNETs) are the most common intracranial tumors. Evidence suggests that these types of tumors may have high recurrence rates. In this context, the purinergic system, oxidative stress, and inflammation are important signaling pathways involved in the cancer’s pathophysiology. This study aimed to evaluate the sociodemographic and diagnostic profiles, as well as assess the purinergic signaling, immunological, and redox profiles, of patients after PitNET resection. We collected sociodemographic data and the patients’ diagnostic profiles. We also collected blood samples to analyze glycemia, triglycerides, albumin, and ATP levels. The ectonucleotidase activity was determined in peripheral blood mononuclear cells (PBMCs). In addition, we evaluated their redox and immunological profiles. There was a prevalence of gonadotropic macroadenoma derived from PIT-1 cells. We found that patients included in the PitNET group had increased glycemia, serum ATP levels, and ATP hydrolysis in PBMCs. Analyzing their immunological profiles, we found that patients had increased levels of IL-6, IL-10, and TNF, while the IL-27 level was decreased. Regarding their redox profiles, PitNET patients had increased levels of ROS and protein carbonylation. Unexpectedly, patients also showed increased levels of non-protein thiols (NPSHs), total thiols (PSHs), and ascorbic acid. Thus, the dysregulation of purinergic signaling sustained chronic inflammation and oxidative imbalance in PitNET patients for a long time after surgical resection. These data suggest that patients with PitNETs require long-term accompanying to prevent cancer recurrence prognosis. The biomarkers highlighted in this study may be good tools to help the medical approaches.

9 June 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Rayana Vilela BertolucciRayana Vilela Bertolucci
Rayana Vilela Bertolucci
Bruna KleinBruna Klein
Bruna Klein
CPCamilla Casarin Pase
Camilla Casarin Pase
VMVitória Capelli de Melo
Vitória Capelli de Melo
MBMARGARETE DULCE BAGATINI
MARGARETE DULCE BAGATINI
Background: Cutaneous melanoma (CM) is a highly immunogenic malignant neoplasm. It features high mutational burden and intense lymphocytic infiltration, supporting the use of immunotherapies, especially inhibitors of the programmed cell death protein 1 (PD-1) checkpoint. Despite advances with anti-PD-1 therapies, such as nivolumab and pembrolizumab, many patients still experience resistance. This result highlights additional immunosuppressive mechanisms within the tumor microenvironment (TME) that limit T-lymphocyte-mediated responses. Objectives: The aim was to discuss the immunologic and metabolic bases of PD-1- and CD73-mediated pathways and evidence that CD73 inhibition can boost PD-1 inhibitor efficacy by acting on convergent immunosuppressive pathways. Methods: We conducted a narrative literature review focusing on tumor immunosuppression, purinergic signaling and checkpoint inhibitor-based immunotherapy. Results: The purinergic pathway, mediated by the ectonucleotidase CD73, is a critical regulator of tumor immunosuppression. CD73 converts extracellular adenosine monophosphate (AMP) into adenosine. This adenosine accumulates in the hypoxic and inflamed TME, exerting immunosuppressive effects. Adenosine acts as a “metabolic brake,” inhibiting proliferation, cytokine production, and cytotoxic activity of CD8+ T lymphocytes and natural killer (NK) cells. It also promotes the expansion of regulatory T cells (Tregs) and tumor progression. This axis may limit responses to PD-1 blockade, suggesting that complementary pathways are active. Conclusions: Integration of PD-1 and CD73 pathways suggests that CD73 inhibition may enhance PD-1 blockade by targeting convergent immunosuppressive mechanisms. This supports the exploration of combination strategies to broaden the benefits of immunotherapy in CM.

2 April 2026 in Purinergic Signalling
Verified
Journal Article
Open access
PDF file
VMVitória Capelli de Melo
Vitória Capelli de Melo
KOKayla I. de Oliveira
Kayla I. de Oliveira
MKMarina Kipper
Marina Kipper
MBMARGARETE DULCE BAGATINI
MARGARETE DULCE BAGATINI
GSGilnei Bruno da Silva
Gilnei Bruno da Silva
Dengue is a globally widespread arboviral disease characterized by an intense inflammatory response that may progress to severe clinical manifestations, such as dengue shock syndrome and hemorrhagic fever. The lack of effective treatments underscores the urgent need to identify new therapeutic targets. In this context, purinergic signaling—mediated by molecules such as ATP and adenosine—has emerged as a central regulator of immune, inflammatory, and vascular responses during dengue virus (DENV) infection. Activation of purinergic receptors, particularly P2X7, directly influences viral replication, cytokine release, and endothelial barrier integrity, potentially contributing either to viral control or to disease severity when dysregulated. This review synthesizes the main mechanisms by which the purinergic system contributes to dengue pathogenesis, emphasizing both its physiological and pathological roles. The molecular analysis indicates that purinergic signaling plays a pivotal role in both restricting and exacerbating viral infection. Therefore, its pharmacological modulation represents a promising avenue for developing innovative therapeutic strategies, particularly for preventing severe dengue outcomes.

22 April 2026 in Clinical Bioenergetics
Verified
Journal Article
Open access
PDF file
VMVitória Capelli de Melo
Vitória Capelli de Melo
GSGabriel Silva Sales
Gabriel Silva Sales
JMJoão Lucas Nunes De Moura
João Lucas Nunes De Moura
MBMARGARETE DULCE BAGATINI
MARGARETE DULCE BAGATINI
GSGilnei Bruno da Silva
Gilnei Bruno da Silva
Cutaneous melanoma is the most lethal form of skin cancer because of its aggressiveness, rapid metastasis, and high therapeutic resistance. The 2018 World Health Organization (WHO) classification emphasized that melanoma comprises distinct subtypes defined by cumulative sun damage, site of origin, and molecular characteristics, which explain differences in mutational burden, immunogenicity, and treatment response. Immunotherapy with anti-PD-1 therapy such as nivolumab and pembrolizumab changed the therapeutic landscape by restoring CD8+ T-cell activity and improving survival. Still, many patients show primary or acquired resistance influenced by low PD-L1 expression, loss of antigen presentation, tumor metabolic plasticity, and an immunosuppressive microenvironment. Mitochondria are central to this process. They regulate ATP generation through oxidative phosphorylation (OXPHOS), redox control, apoptosis, and the metabolic programming needed for T-cell activation. In the tumor microenvironment (TME), hypoxia, nutrient restriction, and PD-1 signaling reduce mitochondrial biogenesis, increase fission and reactive oxygen species (ROS) accumulation, and lead to exhaustion and impaired effector function. Moreover, tumor cells outcompete immune cells for key nutrients such as glucose and glutamine, while increased lactate production and extracellular acidosis further suppress mitochondrial respiration in T cells. Strategies to overcome resistance include restoring oxidative metabolism, activating PGC-1α, supplying metabolic substrates, and combining checkpoint blockade with inhibitors of glycolysis or glutaminolysis to enhance the immune response.

8 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
DMDaiane Manica
Daiane Manica
GSGilnei Bruno da Silva
Gilnei Bruno da Silva
BOBruna Ozelame
Bruna Ozelame
VMVitória Capelli de Melo
Vitória Capelli de Melo
VRVitor Assmann da Rosa
Vitor Assmann da Rosa
MBMARGARETE DULCE BAGATINI
MARGARETE DULCE BAGATINI
Background/Objectives: Cutaneous melanoma (CM) poses a critical public health concern due to its high recurrence rates and resistance to standard treatments. This study investigated the antineoplastic potential of Curcuma Longa L. extract enriched with Bisdemethoxycurcumin (AC3TM) on human melanoma cell lines A375 and SK-MEL-28. Methods: The A375 and SK-MEL-28 cell lines were cultured according to the manufacturer's recommendations and were subsequently treated with different concentrations of AC3TM. The MTT test and fluorescence microscopy were used to assess cell viability. The wound healing assay was used to verify cell migration after treatment with the compound. To determine reactive oxygen species (ROS) levels, we used the fluorescence assay with 2,7-dichlorodihydrofluorescein diacetate. Subsequently, the molecular pathways associated with apoptosis were evaluated using RT-PCR, including the modulation of the inflammatory profile and the components of purinergic signaling. Results: The results revealed that AC3™ effectively inhibited cell proliferation and migration in both melanoma cell lines. In A375 cells, the compound reduced ROS levels and significantly modulated apoptotic pathways, including upregulation of caspase-3 expression. Similarly, in SK-MEL-28 cells, increased expression of caspase-8 and caspase-3 indicated the activation of both intrinsic and extrinsic apoptotic mechanisms. Additionally, AC3™ influenced the inflammatory response by increasing the expression of Tumor Necrosis Factor Alpha (TNF-α), Interleukin 6 (IL-6) and NLR Family Pyrin Domain Containing 3 (NLRP3) in A375 cells while downregulating NLRP3 expression in SK-MEL-28 cells, highlighting its differential immune modulatory effects. Furthermore, the compound modulates the expression and enzymatic activity of ecto-nucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5'-nucleotidase (CD73), key regulators of purinergic signaling, suggesting its ability to impact immune evasion mechanisms in melanoma. Conclusions: These findings position AC3™ as a promising therapeutic candidate for melanoma, targeting critical pathways related to tumor progression, immune regulation, and cellular survival.